Finding your next opportunity shouldn’t require piecing together multiple databases, alerts and research tools.
Fundz combines its own funding and M&A intelligence with hiring, leadership and other business signals into one connected view of each company, ranks opportunities against your ideal customer profile, and delivers the evidence and verified contacts to act on. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Dyne Therapeutics, Inc.
The company shared information publicly (Regulation FD). An 8-K is the notice a US public company must file within four business days of a major event.
dyne-tx.comAI Executive Summary
AI-powered analysis of 8-K filing content
Dyne Therapeutics disclosed new one-year clinical data from its Phase 1/2 ACHIEVE trial evaluating zeleciment basivarsen (DYNE-101) for myotonic dystrophy type 1, along with baseline video hand-opening time metrics for the registrational expansion cohort, signaling progress in its clinical development pipeline.
Key Takeaways
One-year clinical data from the MAD portion of the Phase 1/2 ACHIEVE trial has been disclosed, demonstrating continued progress in DYNE-101 development
Mean baseline video hand-opening time (vHOT) values were announced for the registrational expansion cohort, providing key efficacy measurement data
2 more takeaways
Filing Overview
What This Means
Dyne Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.